Giuseppe Morgia1, Salvatore Voce2, Fabiano Palmieri2, Marcello Gentile3, Gennaro Iapicca3, Antonella Giannantoni4, Franco Blefari5, Marco Carini6, Giuseppe Vespasiani7, Giorgio Santelli8, Salvatore Arnone9, Rosaria M Pareo10, Giorgio Ivan Russo11. 1. Department of Urology, University of Catania, Catania, Italy. 2. Urologic Unit, Lugo of Romagna Division, Ravenna, Italy. 3. Urologic Unit, Avellino Division, Avellino, Italy. 4. Department of Urology and Andrology, University of Perugia, Perugia, Italy. 5. Urologic Unit, Misericordia e Dolce Hospital, Prato, Italy. 6. Department of Urology, Careggi Hospital, University of Florence, Florence, Italy. 7. Department of Urology, University of Tor Vergata, Rome, Italy. 8. Urologic Unit, Lucca Division, Lucca, Italy. 9. Urologic Unit, Ravenna Division, Ravenna, Italy. 10. Urologic Unit, Regina Margherita Hospital, Rome, Italy. 11. Department of Urology, University of Catania, Catania, Italy. Electronic address: giorgioivan@virgilio.it.
Abstract
BACKGROUND: Many potential chemopreventive agents have been used in PCa prevention, including selenium (Se) and lycopene (Ly). However, their role has been matter of debate over the years, due to potential of promotion of PCa. PURPOSE: In this study we aimed at evaluating the incidence risk of prostate cancer (PCa) in a cohort of patients treated with Se and Ly. METHODS: The Procomb trial design has been previously published (ISRCTN78639965). From April 2012 to April 2014 209 patients were followed and underwent prostate biopsy when PSA ≥4 ng/ml and/or suspicion of PCa. The all cohort was composed by patients treated with Se and Ly (Group A = 134 patients) and control (Group B = 75 patients). RESULTS: During the follow-up time of 2 years, a total of 24 patients (11.5%) underwent prostate biopsy, of which 9 (4.3%) where diagnosed with PCa and 15 (7.2%) where diagnosed with benign prostatic hyperplasia. We did not observe statistical differences in terms of mean changes of PSA between the two groups (p-value for trend = 0.33). The relative risk (RR) for PCa was 1.07 and 0.89 in group A and B, respectively (p = 0.95). At the multivariate Cox regression analysis supplementation with Se and Ly was not associated with greater risk of PCa (hazard ratio: 1.38; p = 0.67). CONCLUSION: In this analysis we did not show evidences supporting a detrimental role of Selenium and Lycopene supplementation in increasing PCa after 2 years of therapy, nor supporting a protective role.
RCT Entities:
BACKGROUND: Many potential chemopreventive agents have been used in PCa prevention, including selenium (Se) and lycopene (Ly). However, their role has been matter of debate over the years, due to potential of promotion of PCa. PURPOSE: In this study we aimed at evaluating the incidence risk of prostate cancer (PCa) in a cohort of patients treated with Se and Ly. METHODS: The Procomb trial design has been previously published (ISRCTN78639965). From April 2012 to April 2014 209 patients were followed and underwent prostate biopsy when PSA ≥4 ng/ml and/or suspicion of PCa. The all cohort was composed by patients treated with Se and Ly (Group A = 134 patients) and control (Group B = 75 patients). RESULTS: During the follow-up time of 2 years, a total of 24 patients (11.5%) underwent prostate biopsy, of which 9 (4.3%) where diagnosed with PCa and 15 (7.2%) where diagnosed with benign prostatic hyperplasia. We did not observe statistical differences in terms of mean changes of PSA between the two groups (p-value for trend = 0.33). The relative risk (RR) for PCa was 1.07 and 0.89 in group A and B, respectively (p = 0.95). At the multivariate Cox regression analysis supplementation with Se and Ly was not associated with greater risk of PCa (hazard ratio: 1.38; p = 0.67). CONCLUSION: In this analysis we did not show evidences supporting a detrimental role of Selenium and Lycopene supplementation in increasing PCa after 2 years of therapy, nor supporting a protective role.
Authors: Kalina M Biernacka; Jeff M P Holly; Richard M Martin; Aleksandra Frankow; Caroline J Bull; Freddie C Hamdy; Jenny L Donovan; David E Neal; Chris Metcalfe; Athene Lane Journal: Eur J Cancer Prev Date: 2019-11 Impact factor: 2.497
Authors: Maria G Grammatikopoulou; Konstantinos Gkiouras; Stefanos Τ Papageorgiou; Ioannis Myrogiannis; Ioannis Mykoniatis; Theodora Papamitsou; Dimitrios P Bogdanos; Dimitrios G Goulis Journal: Nutrients Date: 2020-09-29 Impact factor: 5.717
Authors: Alena Mazurakova; Marek Samec; Lenka Koklesova; Kamil Biringer; Erik Kudela; Raghad Khalid Al-Ishaq; Martin Pec; Frank A Giordano; Dietrich Büsselberg; Peter Kubatka; Olga Golubnitschaja Journal: EPMA J Date: 2022-07-08 Impact factor: 8.836
Authors: Tracey L Livingstone; Gemma Beasy; Robert D Mills; Jenny Plumb; Paul W Needs; Richard Mithen; Maria H Traka Journal: Nutrients Date: 2019-09-18 Impact factor: 5.717